Atea Pharmaceuticals (AVIR) Accounts Payables (2019 - 2026)

Atea Pharmaceuticals' Accounts Payables history runs 8 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 27.87% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $9.4 million (up 27.87% YoY), while the FY2025 annual figure was $12.9 million, up 190.38% from the prior year.
• Accounts Payables was $9.4 million for Q1 2026 at Atea Pharmaceuticals, down from $12.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $21.1 million in Q1 2024 to a low of $395000.0 in Q3 2023.
• Historically, Accounts Payables has averaged $6.4 million across 5 years, with a median of $4.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables sank 94.96% in 2022, then surged 2919.57% in 2024.
• A 5-year view of Accounts Payables shows it stood at $2.6 million in 2022, then jumped by 66.68% to $4.3 million in 2023, then increased by 4.84% to $4.5 million in 2024, then jumped by 190.38% to $12.9 million in 2025, then fell by 27.03% to $9.4 million in 2026.
• The last three Accounts Payables figures came in at $9.4 million (Q1 2026), $12.9 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.